Nobel laureate publishes novel hypothesis on curing late-stage cancers

January 8, 2013

In a new paper he regards "among my most important work since the double helix," Nobelist James Watson sets forth a novel hypothesis regarding the role of oxidants and antioxidants in cancers that are currently incurable, notably in late-stage metastatic cancers.

"Although mortality from many cancers has been steadily falling, particularly those of the blood [i.e., leukemias], the more important statistic may be that so many epithelial cancers (carcinomas) and effectively all mesenchymal cancers (sarcomas) remain largely incurable."

With these words as preface, James D. Watson, Ph.D., in a newly published paper that he regards "among my most important work since the ," sets forth a novel regarding the role of and antioxidants in cancers that are currently incurable, notably in late-stage metastatic cancers.

At the heart of his thesis are the group of molecules that scientists call reactive , or ROS. Noting their fundamental two-sidedness, Watson calls ROS "a positive force for life" because of their role in apoptosis – an internal program that highly stressed cells use to commit suicide. It's one of the key mechanisms that have arisen through of evolution to weed out biological dysfunction that poses a threat to the survival of organisms. On the other hand, ROS are also well understood – indeed are notorious – "for their ability to irreversibly damage key proteins and nucleic [e.g., DNA and RNA]."

When they're not needed to curb wayward or out of control cells, which is to say under normal circumstances, ROS are constantly being neutralized by anti-oxidative proteins. We are often urged to eat foods rich in antioxidants such as blueberries; but, if Watson is correct about the role of ROS and antioxidants in late-stage cancer, as he writes in his new paper, " best be eaten because they taste good, not because their consumption will lead to less cancer."

Understanding why this might be so – why antioxidants can in late-stage cancers actually promote cancer progression—is central to Watson's paper, which appears online January 9 in Open Biology, a journal of Great Britain's Royal Society.

He proposes that the cell-killing ability of currently used anti-cancer therapies – toxic chemotherapeutic agents such as Taxol as well as radiation treatment – is mainly due to the action of ROS to induce apoptosis, or programmed cell death. This would explain "why cancers that become resistant to chemotherapeutic control become equally resistant to radiotherapy." The common feature would be their common dependence upon a ROS-mediated cell-killing mechanism.

Watson, who is Chancellor Emeritus of Cold Spring Harbor Laboratory, then takes up the case of cancer cells largely driven by mutant proteins such as RAS and MYC. These, he notes, are often hardest to get to respond to treatment. He suggests this could be due to their high levels of ROS-destroying antioxidants. He cites recent research showing up-regulation of a gene transcription factor called Nrf2 when cells proliferate as well as when oncogenes such as RAS, MYC and RAF are active. Nrf2 controls the synthesis of antioxidants, and "this makes sense because we want present when DNA functions to make more of itself," Watson writes.

In calling for "a much faster timetable for developing anti-metastatic drugs," the Nobel laureate wants those reading his new paper to consider a proposition he considers grossly underexplored: "Unless we can find ways of reducing antioxidant levels, late-stage cancer 10 years from now will be as incurable as it is today."

Explore further: Study identifies an expanded role for PKM2 in helping cancer cells survive

Related Stories

Study identifies an expanded role for PKM2 in helping cancer cells survive

November 3, 2011
It has long been known that cancer cells use nutrients differently than normal cells. In recent years, the rapidly reemerging field of cancer metabolism has shed new light on the ways that cancers use glucose to grow and ...

Tumor suppressor genes vital to regulating blood precursor cells in fruit flies

September 5, 2012
UCLA stem cell scientists have shown that two common tumor suppressor genes, TSC and PTEN, are vital to regulating the stem cell-like precursor cells that create the blood supply in Drosophila, the common fruit fly.

'Detox protein' is collaborator in pancreatic and lung cancer development

July 6, 2011
(Medical Xpress) -- UK scientists have revealed that a ‘detox’ protein which mops up harmful 'reactive oxygen' in cells could also trigger pancreatic and lung cancer development, according to a study published in ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.